Omeros Corporation

392 articles with Omeros Corporation

• Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA

  10/22/2020

  Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved therapy. Narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), the

• Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit

  10/16/2020

  Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made b

• Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA

  10/15/2020

  Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be presented in a webcast on Thursday, October 22, 2020 at 8:30 a.m. ET by Miguel Perales, M.D, Chief of the Adult Bone Marr

• Omeros to Present at the Cantor Virtual Global Healthcare Conference - Sep 11, 2020

  9/11/2020

  Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week.

• Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients

  9/3/2020

  Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients , was held on September 2, 2020 and included i

• 

  Clinical Catch-Up: August 10-14

  8/17/2020

  It was a very busy week for clinical trial updates. Here’s a look.

• Omeros Announces Pricing of Public Offerings - Aug 12, 2020

  8/12/2020

  Omeros Corporation announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock at a public offering price of $14.50 per Share for proceeds of approximately $100,050,000, prior to the deduction of underwriting discounts and commissions and estimated offering expenses payable by Omeros, and $210,000,000 aggregate principal amount of 5.25% convertible senior notes due 2026.

• Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome

  8/10/2020

  -- All six patients, requiring mechanical ventilation prior to treatment, recovered, survived and were discharged from the hospital -- Narsoplimab treatment was associated with rapid and sustained improvement across all assessed markers of endothelial/cellular damage and/or inflammation -- Omeros is in discussions with U.S. government agencies regarding acceleration of narsoplimab manufacturing for use in COVID-19 patients

• Omeros Corporation Reports Second Quarter 2020 Financial Results

  8/10/2020

  Omeros Corporation announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2020

• 

  Biopharma Update on the Novel Coronavirus: August 10

  8/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.

• Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress

  6/12/2020

  Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 25th Congress of the European Hematology Association (EHA) . The EHA oral presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopo

• Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress

  6/11/2020

  Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hematology Association Congress. The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-A

• Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress

  5/14/2020

  Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25 th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually. The presentation, entitled Narsoplimab (OMS721) for the Treatm

• Omeros Corporation Reports First Quarter 2020 Financial Results

  5/11/2020

  Omeros Corporation announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2020, which include:

• Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020

  5/5/2020

  Omeros Corporation, announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes.

• Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA

  3/2/2020

  Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint.

• Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results

  3/2/2020

  – Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market

• Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020

  2/24/2020

  Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes.

• Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors

  2/11/2020

  Feb. 11, 2020 13:30 UTC -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- SEATTLE--( BUSINESS WIRE )-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and fin

• Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors

  12/16/2019

  This presentation included new data from human ex vivo studies demonstrating that GPR174 inhibition results in downregulation of checkpoint and tumor-promoting factors.